Quantitative morphometry of renal biopsies prior to cyclosporine in nephrotic syndrome by Johnson, Kent J. et al.
Original article
Quantitative morphometry of renal biopsies prior to cyclosporine 
in nephrotic syndrome
William E. Smoyer1, Melissa J. Gregory3, Ravinder S. Bajwa2, Kent J. Johnson2, and Timothy E. Bunchman1
1 Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA
2 Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
3 Department of Pediatrics, University of Rochester, New York, USA
&misc:Received June 9, 1997; received in revised form October 14, 1997; accepted January 13, 1998
&p.1:Abstract. Use of cyclosporine (CsA) in the management
of children with steroid-resistant (SRNS) and steroid-de-
pendent (SDNS) nephrotic syndrome has become in-
creasingly popular in recent years. Although most chil-
dren receive a renal biopsy prior to initiation of CsA, the
relationship between initial renal histology and the sub-
sequent clinical response to CsA is not known. We ana-
lyzed the correlation between pre-CsA segmental and
global glomerular scarring and interstitial fibrosis and
the subsequent response to CsA in 23 children (5.6±1.0
years, Mean±SEM) with SDNS (n=8) and SRNS (n=15)
treated with CsA for 24.2±3.8 months and followed for
28.0±4.1 months. Complete remission was obtained in
78% of patients within 67.6±16 days, while 18% had a
partial response and 4% no response. Quantitative histo-
logical analysis revealed a trend toward partial rather
than complete response with increasing segmental glom-
erular (P=0.13), global glomerular (P=0.05), and inter-
stitial (P=0.08) scarring, and among patients with mini-
mal change nephrotic syndrome versus IgM nephropathy
versus focal segmental glomerulosclerosis. Among com-
plete responders, linear regression analyses revealed no
correlation between time to response and pre-CsA glom-
erular or interstitial scarring. We conclude that increased
glomerular or interstitial scarring on a pre-CsA renal bi-
opsy tends to correlate with a partial, rather than com-
plete, response to CsA in childhood nephrotic syndrome.
&kwd:Key words: Interstitial fibrosis – Glomerulosclerosis –
Focal segmental glomerulosclerosis – IgM nephropathy
Introduction
The use of cyclosporine A (CsA) in the management of
childhood nephrotic syndrome has become increasingly
popular in the last several years. It has been reported to
be highly effective in the management of patients with
steroid-dependent nephrotic syndrome (70%–100% re-
sponse rate), but somewhat less effective in those with
steroid-resistant nephrotic syndrome (0%–100% re-
sponse rate) [1–10]. The response to CsA in both adult
and pediatric studies has also been reported to correlate
with initial renal histology, with patients with minimal
change nephrotic syndrome (MCNS) on renal biopsy
having a better response than those with focal segmental
glomerulosclerosis (FSGS) [11–17].
Despite its effectiveness, many concerns remain re-
garding the long-term use of CsA for childhood nephrot-
ic syndrome. The most-serious concern stems from the
risk of CsA nephrotoxicity, characterized by the devel-
pment of irreversible interstitial fibrosis [18]. The re-
ported incidence of CsA nephrotoxicity among patients
with nephrotic syndrome ranges from 0%–100%, with
some reports noting a higher incidence of nephrotoxicity
among patients with steroid-resistant compared with ste-
roid-dependent nephrotic syndrome [1, 4, 5, 19–22]. Be-
cause of these concerns, most patients receive a renal bi-
opsy prior to the introduction of CsA to document the
extent of pre-existing interstitial fibrosis and to establish
a baseline histological diagnosis. The ability to identify
on initial renal biopsy those patients who would be least
likely to benefit from CsA therapy would permit neph-
rologists to avoid subjecting those patients to the risks
associated with CsA use. Unfortunately, no data corre-
lating the extent of pre-existing glomerular or interstitial
scarring with the clinical response to CsA have previous-
ly been reported.
We recently reported a high CsA response rate among
patients who fell into groups with historically poor CsA
response rates: (1) steroid-resistant patients [complete
response in 13/15 (87%) patients], (2) African-American
patients [complete response in 4/5 (80%) patients], and
(3) patients with FSGS on pre-CsA renal biopsy [com-
plete response in 5/5 (100%) patients] [10]. This good
CsA response rate even among patients with FSGS led
us to hypothesize that a pre-CsA renal biopsy may be of
little value in predicting the clinical response to CsA in
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childhood nephrotic syndrome. In an attempt to test this
hypothesis, the present report describes a detailed analy-
sis of pre-CsA renal biopsies from 23 children with ste-
roid-dependent or steroid-resistant nephrotic syndrome,
and correlates these findings with the subsequent clinical
response of these children to CsA over 1–3 years.
Patients and methods
Patients
All patients included in this study had one of the following clini-
cal indications for the introduction of CsA therapy: (1) steroid-de-
pendent nephrotic syndrome (n=8), defined as complete remission
following 4–8 weeks of daily steroids, with relapse soon after
transition to alternate-day therapy and evidence of steroid toxicity
or (2) steroid-resistant nephrotic syndrome (n=15), defined as ab-
sence of a partial or complete remission following an initial
course of at least 4–8 weeks of daily steroids. Of the 15 patients in
the latter group, 12 received 8 weeks of daily steroids. The re-
maining 3 patients had received 4–6 weeks of daily steroids with
the development of severe complications of nephrotic syndrome,
e.g, thrombosis, when CsA therapy was begun.
Written consent for renal biopsy was obtained from all patients
or their parents prior to introduction of CsA. Each patient was
monitored closely throughout the study period, with frequent mea-
surements of blood pressure, serum creatinine, and CsA levels.
Clinical management
Initial therapy for all patients included daily prednisone at 2
mg/kg per day divided twice daily, with a maximal dose of 80
mg/day. Following induction of complete remission for 5–7 days,
the total daily dose was administered in the morning, followed by
gradual tapering. If remission had not been achieved after 8 weeks
of therapy, patients were considered steroid resistant, and trans-
ferred to alternate-day steroids at 2 mg/kg per 48 h. This dose was
continued while CsA was introduced, and tapered only after com-
plete remission was induced. A slow prednisone taper was then
initiated over 3–6 months.
Relapses were managed with prednisone at 2 mg/kg per day
divided twice daily, followed again by slow taper over 2–3 months
after remission was induced. Among patients receiving CsA who
had previously been successfully tapered completely off steroids,
prednisone was restarted and again tapered completely, and the
patients maintained in remission on CsA alone. No changes in tar-
get CsA levels were made.
Complete response was defined as disappearance of proteinur-
ia for at least 7 consecutive days [urine protein negative or trace
by dipstick (or urine protein/creatinine ratio <0.5 in 1 patient)], in
addition to normalization of serum albumin level, and resolution
of edema. Among steroid-dependent patients, complete response
was further defined as maintenance of remission when the steroid
dosage was decreased to levels which had previously resulted in
relapse. Partial response was defined as significant and sustained
improvement in serum albumin, edema, and proteinuria, but with-
out complete normalization.
Many patients had received cytotoxic therapy prior to the in-
troduction of CsA. Among those patients, therapy included a 12-
week course of either cyclophosphamide (2 mg/kg per day) or
chlorambucil (0.2 mg/kg per day). Among steroid-resistant pa-
tients, cytotoxic agents were introduced after at least 8 weeks of
steroid therapy, and the time between the end of the cytotoxic
therapy and introduction of CsA was variable. White blood cell
counts were monitored weekly and dosage adjustments made for
neutropenia.
CsA therapy
Prior to the introduction of CsA, all patients whose serum albumin
levels were less than 2.0 g/dl were treated with intravenous albu-
min (25%, 1–2 g/kg per day) to minimize intravascular volume
depletion that often is present in this setting. Loop diuretics were
also frequently administered during or following the albumin infu-
sions to induce diuresis. Cyclosporine therapy (Sandimmune) was
initiated at approximately 5–8 mg/kg per day, and doses adjusted
to aim for target whole blood high-performance liquid chromatog-
raphy trough levels of 70–120 ng/ml. Levels were followed at 2 to
4-week intervals. Following induction of remission, dosage ad-
justments were made only for trough levels above 120 ng/ml. Pa-
tients who had repeated relapses were maintained at slightly high-
er target CsA trough levels (100–120 ng/ml).
Routine histological evaluation
Renal biopsies were performed under ultrasound guidance using
either a 16- or 18-gauge biopsy needle (Bard, Covington, Ga.,
USA). Biopsy samples were evaluated by light microscopy (using
hematoxylin and eosin, periodic acid-Schiff, trichrome, and Jones
stains), immunofluorescence (IF) microscopy, and electron mi-
croscopy. Each biopsy was reviewed by both a renal pathologist
and pediatric nephrologist. Diagnoses were assigned using stan-
dard histological classifications.
MCNS was defined as minimal or no histological abnormali-
ties on either light or IF microscopy and only diffuse foot process
effacement on electron microscopy.
IgM nephropathy was defined as diffusely increased mesangial
hypercellularity, often with diffusely increased mesangial matrix,
but with minimal or no segmental glomerular sclerosis on light
microscopy, mesangial IgM deposition on IF microscopy, and dif-
fuse foot process effacement with mesangial immune deposits on
electron microscopy.
FSGS was defined as focal glomerular abnormalities with seg-
mental areas of sclerosis on light microscopy, deposition of C3
and IgM on IF microscopy, and diffuse foot process effacement
with mesangial immune deposits on electron microscopy.
The extent of segmental and global glomerular scarring was
determined by a renal pathologist, who analyzed the number of
segmentally and globally scarred glomeruli and the total number
of glomeruli in each biopsy. Values for percentage glomerular
scarring were determined by calculating the percentage of total
glomeruli in each biopsy which had either segmental or global
scarring.
Quantitative digital morphometric histological analysis
Quantitative morphometric analysis of all biopsy tissues was per-
formed to determine the extent of interstitial fibrosis present at the
time of CsA initiation. For this analysis, interstitial areas of tri-
chrome-stained biopsy slides were scanned with a video imaging
system (Olympus BX40 microscope connected to a Sony
CCD/RGB color video camera) at 40× magnification using IP Lab
Spectrum software (Signal Analytic, Vienna, Va., USA) and a
MacIntosh IIfx computer. Scanning windows were set for each
specimen to quantify blue staining representing interstitial fibro-
sis. All available fields were scanned for each biopsy, providing
an average of 23 fields (range 7–62) per biopsy. This quantitative
approach for the measurement of interstitial fibrosis has been re-
ported previously, and has proven highly accurate in the analysis
of the extent of renal scarring [23].
Statistical analyses
Linear regression analyses were used to compare the correlation
between the extent of renal scarring and the subsequent time to
complete response to CsA using Cricket Graph computer graphics
software. A correlation coefficient (r) less than 0.25 was interpret-
ed to indicate little or no relationship between the variables. Com-
parisons between groups was made using unpaired, two-tailed -
tests.
Results
A total of 23 patients (aged 1.5–15.5 years) were includ-
ed in the study. Of the 23 patients, 11 (48%) were fe-
male and 4 (17%) were African American. The mean
age at the time of diagnosis was 5.6±1.0 (±SEM) years
and the mean age at initiation of CsA was 6.7±1.0 years,
resulting in a mean duration of nephrotic syndrome prior
to CsA of 1.1±0.4 years. At the time of CsA introduc-
tion, 15 of 23 patients (65%) were steroid resistant,
while 8 of 23 (35%) were steroid dependent. Twenty pa-
tients (87%) had previously received treatment with cy-
totoxic agents, including 13 of 15 (87%) steroid-resis-
tant patients and 7 of 8 (88%) steroid-dependent pa-
tients. Renal biopsies performed prior to introduction of
CsA revealed MCNS in 1 patient (4%), IgM nephropa-
thy in 15 patients (65%), and FSGS in 7 patients (31%).
Table 1 shows the details of CsA usage, clinical re-
sponse, and duration of follow-up for the study patients.
The CsA dosages required to maintain trough CsA levels
within the target range were similar over the course of
the study. For the study population as a whole, 22 of 23
patients (96%) had at least a partial response to CsA,
when treated with CsA combined with high-dose alter-
nate-day steroids. These findings are consistent with our
previously reported results in a similar, but not identical,
group of patients (19 of the 23 patients common to both
groups) [10]. Among the 4 patients (18%) who had only
partial responses to CsA, the mean serum albumin in-
creased from 2.8 to 3.7 g/dl and the mean urinary protein
to creatinine ratio decreased from 4.92 to 1.91.
Following the introduction of CsA, serum creatinine
values were monitored at 1 to 3-month intervals. Com-
parison of the mean serum creatinine values prior to CsA
(0.45±0.04 mg/dl, ±SEM), after 6 months of CsA thera-
py (0.51±0.05 mg/dl), and after 12 months of CsA thera-
py (0.49±0.05 mg/dl) revealed no apparent significant
effect of CsA on renal function.
Both glomerular and interstitial histological charac-
teristics of the pre-CsA renal biopsies were determined
for the entire study group. The average number of glo-
meruli per biopsy was 18.2±2.4, which confirms that the
biopsy specimens were adequate for analysis. The mean
number of glomeruli per biopsy with segmental scarring
was 0.83±0.3 (4.3%±1.6%), while the mean number of
glomeruli per biopsy with global scarring was 1.0±0.6
(6.2%±3.3%). Quantitative digital morphometric analy-
sis of the entire interstitium in each biopsy specimen re-
vealed that the mean percentage of the interstitium per
biopsy with interstitial fibrosis was 10.1%±0.9%.
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Table 1.Cyclosporine (CsA) usage, clinical response, and follow-up (n=23 patients)&/tbl.c:&tbl.b:
Starting CsA dosage 7.2±0.6 mg/kg per day
Final CsA dosage 7.4±0.7 mg/kg per day
Average trough HPLC CsA level 90.7±3.8 ng/ml
Response to CsA Complete or partial
remission [22 patients (96%)]
Complete remission [18 patients (78%)]
Partial remission [4 patients (18%)]
No response [1 patient (4%)]
Time to CsA response 67.6±16 days
Maintenance in remission 22%
on CsA monotherapy
(prednisone stopped)
Total time on CsA 24.2±3.8 months
Duration of follow-up 28.0±4.1 months
HPLC, High-performance liquid chromatography&/tbl.b:
Fig. 1. Comparison of renal scarring based on pre-cyclosporine
(CsA) renal histological diagnosis. The relationship between pre-
CsA renal histology minimal charge nephrotic syndrome (MCNS),
IgM nephropathy (IgM), [or focal segmental glomerlosclerosis
(FSGS)] and the extend of segmental and global glomerular scar-
ring (% of glomeruli involved), and interstitial fibrosis (as ana-
lyzed using digital morphometric quantitation of the entire inter-
stitium of each biopsy specimen) is shown. A trend toward in-
creased segmental and global glomerular and interstitial scarring
was noted in patients with MCNS vs. IgM vs. FSGS. P=NS for
FSGS vs. IgM for all types of scarring; n=1 patient with MCNS,
15 with IgM, and 7 with FSGS&/fig.c:
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In contrast to the above data for the entire study pop-
ulation, Fig. 1 displays a comparison between the extent
of renal scarring in each of the three pre-CsA renal his-
tological groups. Consistent with the histological defini-
tions, no glomerular scaring was present in the patient
with MCNS. Minimal segmental glomerular scaring
was noted in 3% of glomeruli from patients with IgM
nephropathy compared with 7.8% of glomeruli from
those with FSGS (P=NS for FSGS vs. IgM). Global
glomerular scaring was seen in 3.4% of glomeruli from
patients with IgM nephropathy, while it was found in
13% of glomeruli from patients with FSGS (P=NS for
FSGS vs. IgM). Quantitaive digital morphometric anal-
ysis of the entire interstitium from each biopsy revealed
3.0% interstitital fibrosis in the patient with MCNS,
10.4% in those with IgM nephropathy, and 10.5% in
those with FSGS (P=NS for FSGS vs. IgM).
Following the introduction of CsA, a detailed analysis
was performed of the relationship between several pre-
CsA renal biopsy parameters (histological diagnosis,
segmental and global glomerular scaring, and interstiti-
al fibrosis) and the subsequent response to CsA. The
clinical response to CsA therapy for each of the three
histological groups is shown in Fig. 2. Although the ma-
jority of patients in each group had a complete response
to CsA, a trend toward a partial rather than complete re-
sponse was seen among patients with MCNS versus IgM
nephropathy versus FSGS. Despite this, a partial or com-
plete response was seen in 100% of those with FSGS or
MCNS, compared with 93% of patients with IgM neph-
ropathy. Among patients who had a complete response
to CsA, the mean time to response was 60 days for the
patient with MCNS (n=1), 61±18.5 days for those with
IgM nephropathy (n=12), and 86±36.5 days for those
with FSGS (n=5) (P=NS for FSGS vs. IgM).
Figure 3 shows the overall relationship between the
type and extent of renal scarring and the clinical re-
sponse to CsA for all 23 patients. A trend toward a par-
tial rather than a complete response to CsA was seen
with more-extensive segmental glomerular scaring
(P=0.13), global glomerular scaring (P=0.05), and in-
terstitial scaring (P=0.08). Despite this, the only patient
who had no response to CsA had no segmental or global
glomerular scaring, and markedly less interstitial fibro-
sis (3.8%) than those patients with either a partial
(13.8%) or complete (9.6%) response. Thus, increased
glomerular (segmental or global) or interstitial scaring
correlated with a partial rather than complete clinical re-
sponse to CsA, but not with CsA resistance.
For the 18 patients (78%) in the study who had a
complete response to CsA, linear regression analyses
were used to determine the correlation between each of
the types of renal scarring and the time to complete r-
sponse to CsA (Fig. 4). Figure 4a shows the corelation
between segmental glomerular scaring and the time to
complete response, while Fig. 4b shows the correlation
between global glomerular scaring and complete re-
sponse, and Fig. 4c the corelation between interstitial fi-
brosis and complete response. These analyses revealed
essentially no corelation between the extent of segmen-
tal glomerular scaring (r=0.08) or interstitial fibrosis
(r=0.15) and the time to complete clinical response to
CsA. Interestingly, a weak negative corelation (r=0.25)
was seen between the extent of global glomerular scar-
ring and the time to complete CsA response.
Fig. 2. Comparison of the clinical response to CsA based on pre-
CsA renal histological diagnosis. The relationship between the
Pre-CsA renal histological diagnosis (MCNS, IgM, and FSGS)
and the percentage of patients who had a complete, partial, or no
response to CsA is shown. The majority of patients in each group
had a complete response to CsA, although a trend toward partial
rather than complete response was seen among patients with
MCNS vs. IgM vs. FSGS. Despite this, 100% of patients with
FSGS (and the patient with MCNS) had at least a partial response,
compared with 93% of those with IgM. n=1 patient with MCNS,
15 with IgM, and 7 with FSGS&/fig.c:
Fig. 3. Relationship between the type and extent of renal scarring
and the clinical response to CsA. A comparison of the relationship
between the extent of segmental glomerular scaring, global glom-
erular scaring, and interstitial fibrosis on pre-CsA renal biopsy,
and the subsequent clinical response to CsA is shown. A trend to-
ward a partial rather than a complete response to CsA was seen
with more-extensive scaring of each of the three types. The only
patient who had no response to CsA, however, had no segmental
or global glomerular scaring, and less interstitial fibrosis (3.8%)
than those patients with either a complete (9.6%) or parti l
(13.8%) response. The findings sugest that moderately increased
scaring of any type may be predictive of a partial, rather than
complete, clinical response to CsA, but not resistance to CsA.
*P=0.05 vs. complete response, n=18 patients with complete, 4
with partial, and 1 with no response&/fig.c:
Discussion
Because of the clinical efficacy of CsA in the manage-
ment of children with steroid-dependent and steroid-re-
sistant nephrotic syndrome, its use will almost certainly
continue to increase in the future. Since there are poten-
tially serious risks associated with its use, identification
of specific situations in which it would be unlikely to be
effective could provide important guidelines for direct-
ing therapy in these patients. Although the majority of
nephrotic patients who are begun on CsA receive a renal
biopsy prior to the introduction of CsA, the value of the
biopsy in predicting the subsequent clinical response to
CsA has not been clearly defined.
Several poor prognostic indicators for the response to
CsA in nephrotic syndrome have previously been report-
ed. These include African-American race [24], steroid
resistance [4, 18], and the presence of FSGS on renal bi-
opsy [8, 11]. The relationship between mesangial hyper-
cellularity and IgM deposits (IgM nephropathy) and the
response to CsA has not been often reported, but in our
experience this group of patients was highly responsive
to CsA (93% complete remission) [10]. This histological
lesion, including increased mesangial hypercellularity
and matrix with mesangial IgM deposition, has been re-
ferred to as IgM nephropathy, although some patholo-
gists do not recognize it as a specific pathological lesion.
The present study attempted to identify what pre-CsA
renal biopsy parameters, if any, could aid the clinician in
estimating a nephrotic child’s likelihood of responding
to CsA. Our findings represent a comprehensive, quanti-
tative analysis of the relationship between the clinical re-
sponse to CsA and several important pre-CsA renal bi-
opsy parameters, including: (1) histological diagnosis,
(2) segmental glomerular scarring, (3) global glomerular
scarring, and (4) interstitital fibrosis. To our knowledge,
no similar analysis of this relationship has previously
been reported.
Our results revealed a trend toward a partial, rather
than complete response to CsA among patients with
MCNS versus IgM nephropathy versus FSGS, consistent
with previous reports [8, 12, 15]. Although too few pa-
tients were analyzed to permit a meaningful statistical
comparison between the groups, clearly a majority of
patients with both IgM nephropathy and FSGS had a
complete response to CsA, and 100% of patients with
FSGS had at least a partial response compared with 93%
of those with IgM nephropathy. Although these response
rates compare favorably with other reports [8, 11], a
more-important observation was that no specific renal
histological diagnosis was clearly associated with a poor
response to CsA (i.e., CsA resistance).
Comparison of the extent of each of the three types of
renal scarring with the response to CsA also revealed a
trend toward a partial, rather than complete, response to
CsA among patients with increased segmental glomeru-
lar, global glomerular, or interstitial scarring. Among the
three types of scarring, increased global glomerular scar-
ring revealed the strongest trend (P=0.05) toward pre-
dicting a partial response, and would likely gain statisti-
cal significance in a larger patient population. Despite
this trend, the single patient who had no response to CsA
had no glomerular scarring and less interstitial scarring
than patients with either a complete (n=18) or partial
(n=4) response. The present findings thus suggest that
moderately increased renal scarring of any type may be
predictive of a partial, rather than complete, clinical re-
sponse to CsA, but not resistance to CsA.
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Fig. 4. Relationship between renal scarring and complete clinical
response to CsA. a shows the correlation between pre-CsA seg-
mental glomerular scarring and the time to complete clinical re-
sponse to CsA among the 18 patients who had a complete re-
sponse; b shows the correlation between pre-CsA global glomeru-
lar scarring and the time to complete clinical response to CsA;
c shows the correlation between pre-CsA interstitial fibrosis and
the time to complete clinical response to CsA. No correlation was
seen between segmental glomerular scarring or interstitial fibrosis
and the time to complete response to CsA, and only a weak nega-
tive correlation between global glomerular scarring and the time
to CsA response. These findings suggest that increased glomerular
or interstitial scarring on a pre-CsA renal biopsy does not prolong
the time to clinical response among patients who have complete
responses to CsA
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Identification of only 1 patient who failed to respond
to CsA clearly limits the ability of this study to rigorous-
ly quantitate the predictive value of a pre-CsA renal bi-
opsy. This point is far overshadowed, however, by the
observation that pre-CsA renal biopsies in a group of pa-
tients with IgM nephropathy and FSGS, and variable ex-
tents of glomerular and interstitital scarring, did not dis-
tinguish any subset of patients unlikely to respond to
CsA (i.e., CsA-resistant patients). Indeed, this excellent
response rate is perhaps the most compelling indicator of
the potential effectiveness of CsA in patients with neph-
rotic syndrome, regardless of the underlying histological
findings.
In the absence of evidence to suggest that a pre-CsA
renal biopsy could identify patients who would be CsA
resistant, we sought to determine if it could predict the
time to response among those patients with a complete
response. Linear regression analyses of the correlation
between the extent of glomerular and interstitial scarring
and the time to complete CsA response revealed that no
correlation was present. These findings suggest that in-
creased glomerular or interstitial scarring on a pre-CsA
renal biopsy does not prolong the time to clinical re-
sponse among patients who subsequently have a com-
plete response to CsA.
The lack of a clear correlation between pre-CsA renal
biopsy findings and the subsequent clinical response to
CsA in this study raises some potentially important is-
sues in this era of increasing cost containment. Histori-
cally, the standard of care at most institutions has been
to perform a renal biopsy prior to the introduction of
CsA for the management of children with nephrotic syn-
drome. The rationale for this has usually been that hav-
ing a histological diagnosis would be helpful in guiding
management decisions, and that establishing a baseline
level of interstitial fibrosis was critical to monitor poten-
tial development of CsA nephrotoxicity. The present
findings suggest that a renal biopsy may not be helpful
in predicting whether a given patient will respond to
CsA, and that an empirical trial of CsA could be consid-
ered. We belive that such an approach would be unwise
in that it would preclude the nephrologist from being
able to distinguish progressive interstitial fibrosis (CsA
nephrotoxicity) from pre-existing scarring in those pa-
tients who subsequently develop renal insufficiency
while receiving CsA. Despite this very serious risk, if
the findings in this study prove to be true in larger
groups of patients, it is possible that increasing pressure
will be placed on nephrologists in the future for the stan-
dard of care to shift away from the use of pre-CsA renal
biopsies. Finally, it is important to point out that the pa-
tients evaluated in this study all had essentially normal
age-adjusted serum creatinine values. Extrapolation of
these results to patients with moderate, or even mild, re-
nal insufficiency would clearly be inappropriate.
In summary, the present study represents a compre-
hensive, quantitative analysis of the relationship between
the clinical response to CsA and several important pre-
CsA renal biopsy parameters, including: (1) histological
diagnosis, (2) segmental glomerular scarring, (3) global
glomerular glomerular or interstitial scarring, and (4) in-
terstitial fibrosis. Our findings revealed a trend toward a
partial rather than complete response to CsA, but not
CsA resistance, among patients with increasing
glomerular and interstitial scarring, and among patients
with MCNS versus IgM nephropathy versus FSGS.
Among those patients who had a complete response, no
correlation was found between the time to complete re-
sponse and the extent of pre-CsA glomerular or intersti-
tial scarring. We conclude that increased segmental
glomerular, global glomerular, or interstitial scarring on
a pre-CsA renal biopsy tends to correlate with a partial,
rather than complete, response to CsA in childhood
nephrotic syndrome.
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